Sarepta Therapeutics (NASDAQ: SRPT) options priced for movement into expected FDA decision
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) is recently up $3.35 to $28.95 in the premarket on hope for a decision on the delayed FDA decision regarding eteplirsen. September call option implied volatility is at 131, September weekly is at 147, October is at 187; compared to its 52-week range of 68 to 399.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CBOE (CBOE) Announces New SPX Options Implied Volatility-Based Index: SMILE
- Sarepta's (SRPT) Exondys 51 covered by Humana (HUM) with prior authorization - Bloomberg
- VMWare (VMW) puts more active than calls into Q3 and outlook
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!